Lymphoma
SGN-35 for CD30-positive Malignancies/Previous SGN-35 study (UW09044)
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Investigator: Ajay Gopal, MD ; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT00947856
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Investigator: Oliver Press, M.D.; Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01290549
A Phase II Study to Assess the Efficacy and Safety of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Investigator: Ajay Gopal, MD ; Conditions: Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma, Marginal Zone B-Cell Lymphoma; Status: Recruiting; Study ID: NCT01282424
A Phase 2 Study to Assess the Efficacy and Safety of CAL 101 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Investigator: Ajay Gopal, MD ; Conditions: Hodgkin Lymphoma; Status: Recruiting; Study ID: NCT01393106
Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Investigator: David Maloney, MD, PhD; Conditions: Follicular Lymphoma; Status: Recruiting; Study ID: NCT01200589
A Phase 1b/2 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Investigator: Ajay K. Gopal, MD; Conditions: Relapsed Indolent B-cell Lymphoma; Status: Recruiting; Study ID: NCT01317901
A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With Systemic Anaplastic Large Cell Lymphoma
Investigator: Andrei Shustov, M.D.; Conditions: Anaplastic Large-Cell Lymphoma; Status: Recruiting; Study ID: NCT01309789
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies
Investigator: Ajay K. Gopal, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01165112
A Phase II Study of Bendamustine (B), Dexamethasone (D), and GCSF (G) for Peripheral Blood Hematopoietic Stem Cell Mobilization
Investigator: Ajay K. Gopal, MD; Conditions: Lymphoma, Multiple Myeloma; Status: Recruiting; Study ID: NCT01110135
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies Or In Combination With Dasatinib In Chronic Myeloid Leukemia (CML)
Investigator: Vivian Oehler, M.D,; Conditions: Hematologic Malignancies; Status: Recruiting; Study ID: NCT00953758
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Investigator: Laura Chow, MD; Conditions: Tumors Characterized by Genetic Abnormalities of ALK; Status: Recruiting; Study ID: NCT01283516
A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma
Investigator: John Thompson, MD ; Conditions: Renal Cell Carcinoma, Non-Hodgkin Lymphoma; Status: Closed; Study ID: NCT01015911
An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations
Investigator: Dr. Ajay Gopal; Conditions: Hodgkin's Lymphoma, , Large-Cell Anaplastic Lymphoma, Non-Hodgkin's Lymphoma; Status: Recruiting; Study ID: NCT01026415
A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy
Investigator: Andrei Shustov, MD; Conditions: Cutaneous T-cell Non-Hodgkin Lymphoma; Status: Recruiting; Study ID: NCT00958074
A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
Investigator: Oliver W. Press, MD, PhD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT00822120
An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin's lymphoma
Investigator: Oliver Press, MD, PhD; Conditions: Non-Hodgkin's Lymphoma (NHL); Status: Recruiting; Study ID: NCT01059630
A Treatment-Option Study of Brentuximab Vedotin (SGN-35) in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Investigator: Andrei Shustov, MD; Conditions: Hodgkin's LymphomaAnaplastic Large-Cell Lymphoma; Status: Recruiting; Study ID: NCT01196208
A Phase I, Open-label Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma
Investigator: Andrei Shustov, MD; Conditions: Cutaneous T-Cell Lymphoma; Status: Closed; Study ID: NCT00554827
Phase II Trial Of Response-Adapted Chemotherapy Based On Positron Emission Tomography For Non-Bulky Stage I And II Hodgkin Lymphoma
Investigator: Fred Appelbaum, MD; Conditions: Hodgkin's Lymphoma; Status: Recruiting; Study ID: NCT01132807
A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Investigator: Andrei Shustov, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT00865969
A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies
Investigator: Ajay Gopal, MD; Conditions: Lymphoma; Status: Closed; Study ID: NCT00860171
Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma
Investigator: Ajay Gopal, MD; Conditions: Mantle Cell Lymphoma; Status: Recruiting; Study ID: NCT00843050
A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituximab
Investigator: Mohamed Sorror, MD, MSc; Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphoid Leukemia; Status: Recruiting; Study ID: NCT01419795
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
Investigator: Ajay K. Gopal, MD; Conditions: Non-Hodgkin's Lymphoma (NHL); Status: Recruiting; Study ID: NCT01307267
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma
Investigator: Ann Woolfrey, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01193842
Join Us On